Previous 10 | Next 10 |
Summary Shares have lost 15% year to date. Company wisely adopted a platform-agnostic approach to address first-in-class opportunities across the gene therapy pipeline. Danon disease presents their most lucrative opportunity, with conservative peak sales potential exceeding $2...
Rocket Pharmaceuticals press release ( NASDAQ: RCKT ): Q2 GAAP EPS of -$0.83 misses by $0.15 . Cash, cash equivalents and investments as of June 30, 2022, were $321.4 million. For further details see: Rocket Pharmaceuticals GAAP EPS of -$0.83 misses by $0.15 ...
— Reported positive safety data at ASGCT from pediatric cohort of Phase 1 Danon Disease study that demonstrated RP-A501 was well-tolerated; efficacy update across pediatric as well as adult cohorts on track for late Q3 2022 — — Announced top-li...
— Mayo Pujols brings nearly three decades of technical operations and manufacturing experience, of which the past five years have been exclusively focused on cell and gene therapy, from leading biopharma companies including Andelyn Biosciences, Novartis and Celgene ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
Raymond James has initiated Rocket Pharmaceuticals ( NASDAQ: RCKT ) with an outperform rating seeing opportunity with four of its gene therapy programs. The firm has a $22 price target (~36% upside based on Thursday's close). Analyst Timur Ivannikov highlighted the com...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer,...
Rocket is running a number of successful rare disease programs. Their data so far is excellent. They have a decent cash runway. Rocket Pharmaceuticals, Inc. ( RCKT ) aims to cure rare diseases using gene therapy. Its pipeline looks like this: PIPELINE ...
Stifel has increased the price target on gene therapy developer Rocket Pharmaceuticals (NASDAQ:RCKT) on Thursday, citing topline data the company was scheduled to report for its ex-vivo lentiviral gene therapy candidate RP-L201 at a medical event today. The Phase 2 data from a pivotal trial i...
— RP-L201 well-tolerated with durable CD18 expression for all patients in Phase 2 pivotal trial — — 100% overall survival in patients at one year after RP-L201 infusion based on Kaplan-Meier estimate — — All patients showed clinical r...
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...